Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1733
Abstract: Although the prognosis of core‐binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no… read more here.
Keywords: binding factor; scoring system; myeloid leukemia; core binding ... See more keywords
Response kinetics and factors predicting survival in core-binding factor leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0158-1
Abstract: Core-binding factor (CBF) acute myeloid leukemia (AML) is characterized by t(8;21)(q22;q22) and inv(16)(p13;q22)/t (16;16)(p13;q22) abnormalities, and despite mutational and cytogenetic heterogeneity among t(8;21) and inv(16), these entities share similarities in prognosis, are grouped together, and… read more here.
Keywords: regression; response; flag; core binding ... See more keywords
Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0164-3
Abstract: Minimal residual core binding factor AMLs by real time quantitative PCR—initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res. 2006;30:389–95. 8. Weisser M,… read more here.
Keywords: cell; minimal residual; binding factor; core binding ... See more keywords
Core binding factor acute myelogenous leukemia-2021 treatment algorithm
Sign Up to like & getrecommendations! Published in 2021 at "Blood Cancer Journal"
DOI: 10.1038/s41408-021-00503-6
Abstract: Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved… read more here.
Keywords: factor acute; binding factor; myelogenous leukemia; core binding ... See more keywords
Is the revised International staging system for myeloma valid in a real world population?
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.14341
Abstract: Larson, R.A. & Bloomfield, C.D. (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B Study. Journal… read more here.
Keywords: myeloid leukemia; oncology; core binding; acute myeloid ... See more keywords
Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Chemotherapy"
DOI: 10.1159/000512314
Abstract: Although core-binding factor AML (CBF-AML) has a favorable outcome, disease relapses occur in up to 35% of patients. Minimal residual disease (MRD) monitoring is one of the important tools to enable us to identify patients… read more here.
Keywords: binding factor; minimal residual; maintenance; disease ... See more keywords
Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2020008971
Abstract: The blood system serves as a key model for cell differentiation and cancer. It is orchestrated by precise spatiotemporal expression of crucial transcription factors. One of the key master regulators in the hematopoietic systems is… read more here.
Keywords: transcription; binding factor; antisense promoter; core binding ... See more keywords
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2019000492
Abstract: Acute myeloid leukemia (AML) with either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) is referred to as core binding factor (CBF) AML. Although categorized as favorable risk, long-term survival for these patients is only ∼50% to 60%. Mutated (mut)… read more here.
Keywords: myeloid leukemia; calgb 10801; core binding; acute myeloid ... See more keywords
Core Binding Factor β Expression in Ovarian Granulosa Cells Is Essential for Female Fertility.
Sign Up to like & getrecommendations! Published in 2018 at "Endocrinology"
DOI: 10.1210/en.2018-00011
Abstract: Core binding factor β (CBFβ) is a non-DNA-binding partner of all RUNX proteins and critical for transcription activity of CBF transcription factors (RUNXs/CBFβ). In the ovary, the expression of Runx1 and Runx2 is highly induced… read more here.
Keywords: granulosa cells; binding factor; expression; core binding ... See more keywords
Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sign Up to like & getrecommendations! Published in 2019 at "Haematologica"
DOI: 10.3324/haematol.2019.222810
Abstract: Core binding factor acute myeloid leukemia (AML) comprises two subtypes with distinct cytogenetic abnormalities of either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). Since long-term response to chemotherapy in these leukemias is relatively good, allogeneic hematopoietic stem cell transplantation… read more here.
Keywords: factor acute; binding factor; relapse; transplantation ... See more keywords
Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription
Sign Up to like & getrecommendations! Published in 2019 at "Cancers"
DOI: 10.3390/cancers11121973
Abstract: Acute myeloid leukemia (AML), the most common acute leukemia in adults, is a heterogeneous malignant clonal disorder arising from multipotent hematopoietic progenitor cells characterized by genetic and concerted epigenetic aberrations. Core binding factor-Leukemia (CBFL) is… read more here.
Keywords: binding factor; factor leukemia; core binding; leukemia ... See more keywords